Editorial
Percutaneous myocardial laser revascularisation
| The first 150 words of the full text of this article appear below. |
In the
vast majority of patients with angina pectoris caused by underlying
coronary artery disease, effective treatment is available. Most
patients respond to antianginal medication, and for the remainder
either percutaneous coronary revascularisation or coronary artery
bypass grafting can be performed. There are, however, an increasing
number of patients who have angina which is not controlled by medical
treatment and have disease which is not suitable for conventional
revascularisation techniques. Typically, such patients have
atherosclerotic disease throughout their coronary arterial tree, with
no "target" lesions for angioplasty and no "target" vessels for
surgery. In recent years, transmyocardial laser revascularisation
(TMLR) has been evaluated as a treatment option in this patient
population. This technique, which is usually performed through a left
anterolateral thoracotomy, uses laser energy to create transmural
channels in the ischaemic myocardium. The initial experience with TMLR
used a high energy carbon dioxide laser. As a result of developments
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
